Towards Healthcare
Personalized Medicine Market Size, Trends & 8.24% CAGR by 2034

Personalized Medicine Market to Increase $1264.67 Bn by 2034

The personalized medicine market is growing rapidly, leveraging genetic and genomic data to improve prevention, diagnosis, and treatment. With over 75,000 genetic testing kits and 300 personalized medicines available, advancements in NGS technology and NIH research are driving this growth, enhancing patient care.

The global personalized medicine market was evaluated at US$ 572.93 billion in 2024 and is expected to attain around US$ 1264.67 billion by 2034, growing at a CAGR of 8.24% from 2024 to 2034. The ever-increasing personalized medicine market, due to personalized medicine, aims to make more accurate diagnoses, improve treatment outcomes, and reduce side effects by tailoring treatments to each patient's specific needs.

Personalized Medicine Market Size 2023 - 2034

Unlock Infinite Advantages: Subscribe to Annual Membership

Market Overview

The personalized medicine market is growing rapidly as personalized medicine is used in many ways to help prevent, diagnose, and treat diseases. Personalized medicine is a field of medicine that determines the prevention, diagnosis, and treatment of patients based on information obtained from genetic and genomic information. The basic idea of personalized medicine is that information about a patient's genes and genome enables doctors to make smarter, better patient care decisions. Advances in health technology have contributed to the emergence of personalized medicine, which requires the electronic processing and storage of patient information, especially the use of personalized drugs through translation and clinical research.

  • The latest estimates from the Alliance for Personalized Medicine show that more than 75,000 genetic testing kits and 300 personalized medicines are available for patients with a variety of diseases and infections, non-rare genetics, and cancer, leading to advances in the personalized medicine market.
  •  The National Institutes of Health’s (NIH) investment in scientific research has led to many discoveries that underpin personalized prevention and treatment strategies. Facilitating the development and adoption of personalized diagnostics and treatments has led to the growth of the personalized medicine market.
  • PMC President Edward Abrahams launched a joint strategic plan to promote personalized medicine by 2024. Improving the quality of personalized medical products and services.
  • The rapid development of NGS technology has reduced sequencing costs and increased accuracy. The use of NGS testing in the diagnosis of genetic diseases, tumors, hematological malignancies, infectious diseases, human leukocyte antigen screening, and chromosomal problems in the fetus has led to the development of the personalized medicine market.

AI Integration in the Personalized Medicine Market

The integration of AI with personalized medicine is opening up new opportunities for research and treatment. AI algorithms can analyze large amounts of data in a short period, detecting subtle patterns and relationships that might otherwise be overlooked. The personalized medicine market driven by AI has the potential to improve immunity. By analyzing a person’s genetic predispositions, lifestyle choices, and environment, intelligent algorithms can identify individuals at high risk for certain diseases. This early detection allows doctors to implement preventive measures and interventions that reduce disease and improve overall health. The integration of AI in personalized medicine is a possibility for continuous learning and adaptation. AI algorithms can instantly analyze treatment outcomes and patient responses to optimize and refine treatment plans. This iterative process allows interventions to continue to evolve and improve, leading to better outcomes for patients over time.

Market Dynamics

Driver

Recent Advances in Personalized Medicine

Recent advances in genetic analysis molecular diagnostics, and personalized medicine represent a revolution in healthcare. The shift from single-gene testing to a widely used clinical tool using genetic and molecular biomarkers is enabling new changes in the drug discovery process. Pharmacogenomics integrates clinical and patient data into early data sets, accelerating the path to disease treatment and enabling appropriate treatment. This personalized approach is revolutionizing the management of many diseases, including infectious diseases, cancer, autoimmune diseases, neurological diseases, bladder dysfunction, and gynecological conditions. Through the use of genetics, epigenomics, and clinical insights, personalized medicine is not only understanding the disease but also enabling the rapidly expanding personalized medicine market with the ability to the repair process.

Restraint

Challenges in the Personalized Medicine

Despite its transformative potential, the personalized medicine market faces significant challenges that limit its growth. The complexity of genomic variation is a major concern because individual genomes contain millions of variants compared to the HGP used, requiring multidisciplinary analysis to correlate variations with disease or response to treatment. Geographic and ethnic diversity further complicate matters, as genetic variation resulting from environmental and demographic factors can affect individuals differently. Limitations in data analysis and integration continue to hinder progress, while ethical issues, including privacy and fairness, add another layer of complexity. Addressing these various limitations is critical to unlocking the potential of personalized medicine.

Opportunity

Growing Adoption of Imperative of Personalized Medicine

Personalized medicine is changing health by using genetic, environmental, and lifestyle information to optimize disease prevention, diagnosis, and treatment. This approach increases diagnostic accuracy, identifies the best treatment options based on individual characteristics, and simplifies treatment to improve outcomes while reducing side effects. By promoting better immunity and encouraging patient engagement, personalized medicine can not only reduce healthcare costs but also accelerate drug discovery and innovation. The ability to reduce drug toxicity, increase treatment efficiency, and balance the medical system makes personalized medicine a key driver of healthcare advancements worldwide. As technology and knowledge continue to advance, this dynamic field promises to revolutionize healthcare models and deliver better outcomes for patients and providers, which this caused growth of the personalized medicine market.

For Instance,

  • In October 2023, the new European Partnership for Personalized Medicine (EP PerMed) was launched at the Medicines high-level meeting in Valencia. The launch of this partnership promotes precision medicine research in the European research landscape, with 49 partners involved in its development. It will support all areas and disciplines of precision medicine, drive innovation and change, and ensure continuous improvement by promoting its integration into healthcare.

Segmental Insights

The Personalized Nutrition & Wellness Segment Dominated

By Product, the personalized nutrition & wellness segment recorded a dominant personalized medicine market share in 2023, as they provide health advice by combining genetic, phenotypic, and other health-related information. This is essential even for patients who are not genetically susceptible to a particular disease. Personalized nutrition is important when aiming to improve public health. Personalized nutrition brings health recommendations closer to the individual’s daily life. Therefore, recommended dietary patterns are more flexible and long-lasting.

The Personalized Medicine Therapeutics Segment: Fastest CAGR

By product, the personalized medicine therapeutics segment is projected to record the fastest CAGR during the forecast period as it tailors treatments to each patient’s characteristics. The approach is based on a scientific understanding of how an individual’s molecular identity and genetic characteristics predispose them to certain diseases. Personalized medicine uses genetic, environmental, and lifestyle factors to determine the best treatment for a particular individual.

The Hospitals Segment Dominated in 2023

By End-use, the hospital segment led the personalized medicine market with a dominant market share in 2023 as it is a new type of treatment that uses an individual’s genetic makeup to guide decisions about disease prevention, diagnosis, and treatment. Understanding a patient’s genetics can help doctors choose a medication or treatment and provide them with the right dose or regimen. Personalized medicine, including reducing the risk of drug toxicity, increasing the efficacy of medicines, promoting equity in healthcare, and supporting drug discovery and development.

Regional Insights

Personalized Medicine Market NA, EU, APAC, LA, MEA Share, 2023 (%)

Advancements in Medicine Drives North America

North America accounted for the largest share of the personalized medicine market by 41% in 2023 as the development of next-generation sequencing technology and the use of health information systems are helping to expand the North American specialty medicine market. North America has a well-developed healthcare system that is highly advanced in innovation and the use of new technologies. Concerns over chronic diseases such as cancer, heart disease, and diabetes in North America have increased the demand for personalized medicines that can provide more effective and efficient treatment. The region has seen progress in self-diagnosis. The United States and Canada are the major countries in the market. The advancements in science leading to personalized medicine can bring awareness to the public. Personalized medicine is a growing practice that promises to improve patient care while improving treatment outcomes, accelerating the growth of the personalized medicine market.

Rising Clinical Trials Drive Asia Pacific

Asia Pacific’s personalized medicine market is expected to grow at the fastest CAGR during the forecast period, as rising clinical trials of new drugs and diagnostics in this region are highly valued and attract investment from abroad. The need for personalized medicine and new treatments is also increasing in response to the increasing number of diseases in the region. Rising healthcare expenditures and improved healthcare services in developing countries are driving the growth of the economy in this region. The Asia Pacific Personalized Care Index measures the readiness of 11th regional healthcare systems to adopt personalized care. Innovation in precision medicine has skyrocketed, with the Asia Pacific region leading the way. China has begun making advances in genomic research and technology by announcing its precision medicine plans, which has led to the growth of the personalized medicine market.

Personalized Medicine Market Companies

Top Companies in Personalized Medicine Market

  • GE Healthcare
  • Illumina, Inc.
  • ASURAGEN, INC.
  • Abbott
  • Dako A/S
  • Exact Sciences Corporation
  • Danaher Corporation (Cepheid, Inc.)
  • Decode Genetics, Inc.
  • QIAGEN
  • Exagen Inc.
  • Precision Biologics
  • Celera Diagnostics LLC.
  • Biogen
  • Genelex
  • International Business Machines Corporation (IBM)
  • Genentech, Inc.
  • 23andMe, Inc.

Latest Announcements by Industry Leaders

In October 2024, Chicago GE HealthCare is pleased to partner with University Medicine Essen (UME) in the creation of a new Theranostics Center of Excellence with the goal of expanding access to precision care. Ken Herrmann, MD, director and chair of the scientific advisory board at the Clinic for Nuclear Medicine, University Medicine Essen, says that theranostics has transformed the way we approach patient care by fusing precise diagnostic tools with targeted therapy and providing a customized treatment plan. We are able to provide therapies that are customized to the unique situation of each patient because of this expanding practice. In order to improve and extend customized medicine and help guarantee even better results for patients in the future, we must work with industry leaders, such as GE HealthCare, and invest in innovation.

Recent Developments in the Personalized Medicine Market

  • In May 2024, OM1 announced three new products, OM1 Orion, OM1 Lyra, and OM1 Polaris, powered by PhenOMTM, an intelligent digital phenotyping platform for personalized medicine and clinical research. OM1 is a leader in delivering real-world evidence (RWE) insights from the laboratory to the hospital, using advanced predictive and AI techniques and in-depth data analysis to support healthcare stakeholders.
  • In September 2024, Odense-based Evosep provides researchers and partners with integrated tools that enable precision medicine and agile processes through a new partnership with US giant Thermo Fisher Scientific.
  • In February 2023, Roche announced the expansion of its partnership with Janssen Biotech. (Janssen) to create a companion evaluator for healthcare to advance research and innovation of personalized medicine.

Segments Covered in the Report

By Product

  • Personalized Medicine Diagnostics
    • Genetic Testing
    • Direct-to-consumer (DTC) Diagnostics
    • Esoteric Lab Services
    • Esoteric Lab Tests
  • Personalized Medicine Therapeutics
    • Pharmaceutical
    • Genomic Medicine
    • Medical Devices
  • Personalized Medical Care
    • Telemedicine
    • Health Information Technology
  • Personalized Nutrition & Wellness
    • Retail Nutrition
    • Complementary & Alternative Medicine

By End-use

  • Hospitals
  • Diagnostic Centers
  • Research & Academic Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
  • Insight Code: 5382
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: December 2024
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

Meet the Team

Kesiya Chacko is a healthcare market research expert with 4+ years of experience, specializing in analyzing industry trends, assessing market opportunities, and providing actionable insights for businesses in healthcare sectors.

Learn more about Kesiya Chacko

Aditi Shivarkar, with 14+ years of healthcare market research experience, ensures the accuracy, clarity, and relevance of reports. Her expertise helps businesses make informed decisions and stay competitive in healthcare sectors.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

Targeting the appropriate medications to the appropriate patients at the appropriate time is the aim of precision medicine.

A vast and quickly developing area of medicine, personalized medicine is based on the individual clinical, genetic, genomic, and environmental data of each patient.

CDC, National Institutes of Health, WHO, FDA.